Newsroom

Industry News

13 Jan

Arch Therapeutics Obtains Additional Positive Results for AC5 Surgical Hemostatic Device(TM) in Preclinical Safety Study

AC5(TM) Safety Further Supported; Non-Irritant in Animal Testing Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of the AC5 Surgical Hemostatic Device™, obtained positive results when AC5™ was subjected to a standardized medical device test for irritation potential. The irritation test in animals is a major component...

Read more

13 Jan

Relmada Therapeutics Reaches Midway Point in Dose Escalation for Phase One Study of Novel NMDA Receptor Antagonist d-Methadone

Novel product candidate being studied in treatment of neuropathic pain Relmada Therapeutics, Inc. (RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that the company has reached the midway point in a continuing pharmacokinetic and pharmacodynamic study with d-Methadone, the company’s N-methyl-D-aspartate (NMDA)...

Read more

12 Jan

Cure Duchenne Ventures LLC To Provide $1 Million to Capricor Therapeutics to Advance Promising Research to Treat Heart Disease Associated with Duchenne Muscular Dystrophy

NEWPORT BEACH, Calif.–(BUSINESS WIRE)— CureDuchenne Ventures LLC, a company that funds research to find a cure for Duchenne muscular dystrophy that was formed by the nonprofit CureDuchenne, announced today that they are investing $1 million in Capricor Therapeutics, a biotechnology company focused on developing novel therapeutics for the treatment...

Read more

12 Jan

Capricor Therapeutics Announces $10 Million Private Placement of Common Stock

Investors Include: Cedars-Sinai Medical Center, CureDuchenne Ventures LLC, Select Board Members and Capricor Management LOS ANGELES, Jan. 12, 2015 (GLOBE NEWSWIRE) — Capricor Therapeutics, Inc. (CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that it has signed definitive agreements for...

Read more

12 Jan

Capricor Therapeutics Announces Linda Marban, Ph.D. Will Present a Company Overview and Serve as an Expert Panelist at Piper Jaffray’s 26th Annual Healthcare Conference

LOS ANGELES, Dec. 2, 2014 (GLOBE NEWSWIRE) — Capricor Therapeutics, Inc. (CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, announced today that CEO and President Linda Marban will deliver an overview of Capricor Therapeutics, Inc., to Piper Jaffray’s clients during a fireside...

Read more

9 Jan

SurePure Technology Instrumental in Clinical Trial

SurePure, Inc. (SURP) a global leader in liquid photopurification, is pleased to announce that its patented photopurification technology is seen as instrumental in the success of the clinical trials being conducted by Tamarack Biotics. Tamarack Biotics is developing and plans to clinically test milk that has been pasteurized with SurePure’s...

Read more

8 Jan

PCG Advisory Group (PCG) Announces Clients in San Francisco for the J.P. Morgan 33rd Annual Life Sciences Conference, OneMedForum SF 2015 and 7th Annual Biotech Showcase

PCG Advisory Group announced today that 22 clients will be participating in the leading biotech/life sciences forums, which will be held in San Francisco from January 12th to January 15th. PCG’s clients will present corporate updates, participate in investor one-on-one meetings, hold private partnering sessions and interview with select...

Read more

8 Jan

Athersys to Present at Biotech Showcase 2015

Athersys, Inc. (ATHX) announced today that it will present at the Biotech Showcase(TM) 2015 to be held on January 12-14, 2015 in San Francisco, California, at the Parc 55 Wyndham San Francisco — Union Square. William (B.J.) Lehmann, President and Chief Operating Officer, will present on Tuesday, January 13,...

Read more

8 Jan

Anavex Announces Panel Discussion and Presention at OneMedForum Conference

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (AVXL), a clinical stage biopharmaceutical company currently in a Phase2a clinical trial for Alzheimer’s disease, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will participate in a panel discussion entitled “Neurology and Brain Health” and will present...

Read more

Page 221 of 260« First...102030...219220221222223...230240250...Last »

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address